Get the Stockscreener App
1.30
2.99%
-0.04
After Hours:
1.31
0.01
+0.77%
Outlook Therapeutics Inc stock is traded at $1.30, with a volume of 938.30K.
It is down -2.99% in the last 24 hours and up +33.86% over the past month.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
See More
Previous Close:
$1.34
Open:
$1.34
24h Volume:
938.30K
Relative Volume:
0.25
Market Cap:
$57.75M
Revenue:
-
Net Income/Loss:
$-51.50M
P/E Ratio:
-0.325
EPS:
-4
Net Cash Flow:
$-47.10M
1W Performance:
-2.99%
1M Performance:
+33.86%
6M Performance:
-16.13%
1Y Performance:
-75.33%
1-Day Range:
$1.28
$1.34
1-Week Range:
$1.27
$1.48
52-Week Range:
$0.79
$6.98
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Name
Outlook Therapeutics Inc
Sector
Industry
Phone
(609) 619-3990
Address
111 S. WOOD AVENUE, ISELIN, NJ
Compare OTLK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
1.30 | 62.63M | 0 | -51.50M | -47.10M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.63 | 109.29B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.00 | 62.13B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.69 | 61.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.18 | 51.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
310.03 | 34.68B | 4.56B | -176.77M | 225.30M | -1.7177 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-28-25 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-02-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Mar-27-24 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-15-24 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Jan-25-24 | Upgrade | Guggenheim | Neutral → Buy |
| Dec-27-23 | Upgrade | CapitalOne | Equal Weight → Overweight |
| Aug-31-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Aug-31-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-30-23 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-30-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Aug-30-23 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Aug-30-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-13-23 | Initiated | CapitalOne | Overweight |
| Apr-03-23 | Initiated | Guggenheim | Buy |
| Feb-06-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-31-22 | Initiated | BTIG Research | Buy |
| Sep-13-22 | Initiated | Chardan Capital Markets | Buy |
| Sep-11-19 | Initiated | Ladenburg Thalmann | Buy |
| May-16-19 | Initiated | Oppenheimer | Outperform |
| Apr-22-19 | Initiated | Ascendiant Capital Markets | Buy |
View All
Outlook Therapeutics Inc Stock (OTLK) Latest News
What technical models suggest about Outlook Therapeutics Inc.’s comeback - newser.com
Outlook Therapeutics Inc. stock prediction for this week2025 Price Targets & AI Forecast Swing Trade Picks - newser.com
Is Outlook Therapeutics Inc. (41O) stock bottoming after sell off2025 Analyst Calls & Fast Moving Market Watchlists - newser.com
Can Outlook Therapeutics Inc. stock beat analyst upgradesGlobal Markets & Real-Time Buy Zone Alerts - newser.com
Will Outlook Therapeutics Inc. (41ON) stock outperform value peersProduct Launch & Technical Buy Zone Confirmation - newser.com
How to read the order book for Outlook Therapeutics Inc.2025 Technical Patterns & Expert Approved Momentum Ideas - newser.com
Is Outlook Therapeutics Inc. (41ON) stock good for long term investing2025 Market Overview & Low Risk Growth Stock Ideas - newser.com
Full technical analysis of Outlook Therapeutics Inc. stockJuly 2025 Reactions & Safe Capital Preservation Plans - newser.com
What analyst consensus implies for Outlook Therapeutics Inc. (41O) stockWeekly Trading Summary & Pattern Based Trade Signal System - newser.com
Outlook Therapeutics Inc. stock chart pattern explainedWatch List & Free Expert Verified Stock Movement Alerts - newser.com
What drives Outlook Therapeutics Inc 41O stock priceAI-Driven Market Analysis & Consistent Double Returns - earlytimes.in
What earnings margins imply for Outlook Therapeutics Inc. (41O) stockShare Buyback & Verified Trade Idea Suggestions - newser.com
Can Outlook Therapeutics Inc. stock continue upward trendJuly 2025 Big Picture & Weekly Market Pulse Updates - newser.com
Is Outlook Therapeutics Inc. (41ON) stock testing key supportJuly 2025 Intraday Action & Free Weekly Watchlist of Top Performers - newser.com
What is the fair value of Outlook Therapeutics Inc. stock nowMarket Trend Report & Reliable Intraday Trade Plans - newser.com
News impact scoring models applied to Outlook Therapeutics Inc.Portfolio Return Summary & Fast Gain Stock Trading Tips - newser.com
Published on: 2025-10-20 17:10:41 - newser.com
Is Outlook Therapeutics Inc. (41ON) stock attractive for growth funds2025 Market Overview & Long-Term Growth Portfolio Plans - newser.com
What does recent volatility data suggest for Outlook Therapeutics Inc.Product Launch & Stepwise Trade Signal Implementation - newser.com
Will Outlook Therapeutics Inc. (41O) stock split increase liquidityJuly 2025 WrapUp & Smart Allocation Stock Tips - nchmf.gov.vn
How Outlook Therapeutics Inc. stock performs in interest rate cyclesTreasury Yields & High Accuracy Trade Signal Alerts - newser.com
Aug Retail: What analyst consensus implies for Outlook Therapeutics Inc. (41O) stockJuly 2025 Short Interest & Trade Opportunity Analysis Reports - nchmf.gov.vn
Can Outlook Therapeutics Inc. rally from current levelsWeekly Trend Summary & Community Supported Trade Ideas - newser.com
Can Outlook Therapeutics Inc. stock attract ESG capital inflows2025 Volume Leaders & Short-Term High Return Strategies - nchmf.gov.vn
Investment Review: Why Outlook Therapeutics Inc. stock could be next big winnerJuly 2025 Big Picture & Expert Verified Stock Movement Alerts - nchmf.gov.vn
Outlook Therapeutics Inc Stock (OTLK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.03%
0.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):